Total Voting Rights

RNS Number : 4002P
Hikma Pharmaceuticals Plc
01 October 2013
 



 

 

 

 

 

Hikma Pharmaceuticals PLC

Voting Rights and Capital

 

LONDON, 1 October 2013, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) notifies the market that its capital consists of 197,755,028 ordinary shares with voting rights. There are 210,000 shares held in treasury, which do not carry voting rights and have been excluded from the above figure.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Hikma Pharmaceuticals PLC under the FSA's Disclosure and Transparency Rules.

 

- ENDS -

 

Enquiries

 

Hikma Pharmaceuticals PLC

 

Peter Speirs

Company Secretary

 

+44 20 7399 2760

 



 

 

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2012, Hikma achieved revenues of $1,108.7 million and profit attributable to shareholders of $100.3 million. 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TVREAEEFEAADFFF
UK 100

Latest directors dealings